The global human papillomavirus (HPV) vaccine market was valued at approximately USD 3.80 billion in 2019 and is expected to grow significantly, reaching around USD 12.69 billion by 2027. This growth corresponds to a compound annual growth rate (CAGR) of 16.3% over the forecast period. North America led the market in 2019, holding the largest share at 48.16%.
